Novocure (NVCR) Announces FDA Approval of Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. NKE
8. MU
9. USO
10. NVDA

Go back to Novocure (NVCR) Announces FDA Approval of Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer

H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy

October 16, 2024 6:06 AM EDT

H.C. Wainwright analyst Emily Bodnar upgraded NovoCure Ltd. (NASDAQ: NVCR) from Neutral to Buy with a price target of $30.00.

The analyst comments "Optune Lua receives FDA approval with favorable label based on the LUNAR Phase 3 study. Yesterday after market close, Novocure announced that the FDA has approved Optune Lua for the treatment of metastatic NSCLC for use concurrently with PD-(L)1 inhibitors or docetaxel in patients who have progressed on or after a platinum based regimen. The approval was based on the Phase 3 LUNAR study which demonstrated that there was a 3.3... More